Selective in vitvo replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours- evaluation of a potentially effective clinical therapy

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 745-752

  McKie, E A ^a   MacLean, A R ^b   Lewis, A D ^c   Cruickshank, G ^d   Rampling, R ^c   Barnett, S C ^e   Kennedy, P G E ^a   Brown, S M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Institute of Neuro Logical Sciences   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^e Garscube Estate   (United Kingdom)

Author keywords

Cns tumour therapy; HSV 1; ICP34.5 null mutant

Indexed keywords

CELL PROTEIN; GENE PRODUCT; VIRULENCE FACTOR; HERPES SIMPLEX VIRUS, TYPE 1 PROTEIN ICP4; IMMEDIATE EARLY PROTEIN; VIRUS ANTIGEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER CELL CULTURE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CELL DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; GENE DELETION; GLIA CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TARGET CELL DESTRUCTION; VIRUS MUTANT; VIRUS REPLICATION; ANIMAL; BIOPSY; BIOSYNTHESIS; CELL CULTURE; DEFECTIVE VIRUS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; GLIOMA; HAMSTER; HERPES SIMPLEX; ISOLATION AND PURIFICATION; NERVOUS SYSTEM TUMOR; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; BIOPSY; CRICETINAE; DEFECTIVE VIRUSES; GENE EXPRESSION REGULATION, VIRAL; GLIOBLASTOMA; GLIOMA; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MUTAGENESIS, INSERTIONAL; NERVOUS SYSTEM NEOPLASMS; PROTEIN BIOSYNTHESIS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0029665612     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.431     Document Type: Article

References (33)

1. ALBERT FK, FORSTING F, SARTOR K, ADAMS HP AND KUNZE S. (1994). Early post-operative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumour and its influence on regrowlh and prognosis. Neurosurgery, 34, 445 461.
2. ALLALUNIS TMJ, BARRON GM, DAY RS III, DOBLER K AND URTASUN RC. (1992). Heterogeneity in response to treatment with butathione sulfoximine or Interferon in human malignant glioma cells. Int. J. Radiat. Oncol. Biol. Phys., 22, 765-768.
3. BIGNER SH, MARK J, MAHALEY MS AND BIGNER DD. (1984). Patterns of the early gross chromosomal changes in malignant human gliomas. Hereditas, 101, 103-113.
4. BIGNER SH, MARK J, BULLARD DE, MAHALEY MS Jr AND BIGNER DD. (1986). Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations. Cancer Genet. Cytogenet., 22, 121-135.
5. BOTTENSTEIN JE AND SATO GH. (1979). Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc. Natl Acad. Sci. USA, 76, 514-517.
6. BROWN SM, RITCHIE DA AND SUBAK-SHARPE JH. (1973). Genetic studies with herpes simplex virus type 1. The isolation of temperature sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J. Gen. Virol., 18, 329-346.
7. BROWN SM, HARLAND J, MACLEAN AR, PODLECH J AND CLEMENTS JB (1994a) Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5 negative herpes simplex virus. J. Gen. Virol., 75, 2367-2377.
8. BROWN SM, MACLEAN AR, AITKEN JD AND HARLAND J. (1994b). IP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J. Gen. Virol., 75, 3679-3686.
9. CHAMBERS R, GILLESPIE GY, SOROCEANU L, ANDREANSKY S, CHATTERJEE S, CHOU J, ROIZMAN B AND WHITLEY RJ. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl Acad. Sci. USA, 92, 1411-1415.
10. CHANG CH, HORTON J, SCHOENFELD D, SALAZAR O, PEREZ-TAMAYO R, KRAMER S, WEINSTEIN A, NELSON JS AND TSUKADA Y. (1983). Comparison of post-operative radiotherapy and combined post-operative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer, 52, 997-1007.
11. CHOU J AND ROIZMAN B. (1986). The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component. J. Virol., 57, 629-637.
12. CHOU J AND ROIZMAN B. (1992). The γ34.5 gene of herpes simplex virus type 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc. Natl Acad. Sci. USA, 89, 3266 3270.
13. CHOU J, KERN ER, WHITLEY RJ AND ROIZMAN B. (1990). Mapping of herpes simplex virus type 1 neurovirulence to ICP34.5, a gene non-essential for growth in culture. Science, 250, 1262 1265.
14. COEN DM, KOSZ-VNENCHAK M, JACOBSON JG, LEIB DA et al. (1989). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl Acad. Sci. USA, 86, 4736-4740.
15. DOLAN A, MCKIE EM MACLEAN AR AND MCGEOCH DJ. (1992). Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17. J. Gen. Virol., 73, 971 973.
16. FINE H, DEAR KB, LOEFFLER JS, BLACK P AND CANELLOS GP. (1993). Meta-analysis of radiation therapy with or without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71, 2585-2597.
17. KELLY PJ, DUMAS-DUPORT C, KISPERT DB, KALL BA, SCHEITHAUER BW AND ILLIG JJ. (1987). Imaging based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J. Neurol., 66, 865 874.
18. KESARI S, RANDAZZO BP, VALYI-NAGY T, HUANG QS, BROWN SM, MACLEAN AR, LEE VM-Y, TROJANOWSKI JQ AND MACKIE T. (1995). A mutant herpes simplex virus replicates in brain tumours but not in neurons derived from a human embryonal carcinoma cell line. Lab. Invest., 73, 636-648.
19. KORNBLITH PL AND WALKER M. (1988). Chemotherapy for malignant gliomas. J. Neurol., 68, 1-17.
20. + neurovirulence gene RL1 and its expression in a bacterial system. J. Gen. Virol., 75, 733-741.
21. + between immediate early gene 1 and the 'a' sequence. J. Gen. Virol., 72, 631-639.
22. MACPHERSON I AND STOKER MG. (1962). Polyoma transformation of hamster cell clones: an investigation of genetic factors affecting cell competence. Virology, 16, 147-151.
23. MARTUZA RL, MALICK A. MARKERT JM, RUFFNER KL AND COEN DM. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252, 854-856.
24. MARKERT JM, MALICK A, COEN DM AND MARTUZA RL. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery, 32, 597 603.
25. MARSDEN HS, STOW ND, PRESTON VG, TIMBURY MC AND WILKIE NM. (1978). Physical mapping of herpes simplex virus-induced polypeptides. J. Virol., 28, 624 642.
26. MEHTA MP, MASCIOPINTO J, ROSENTHAL J, LEVIN A, CHAPPELL R, BASTIN K, MILES J, TURSKI P, KUBSAD S AND MACKIE T. (1994). Stereotactic radiosurgery for glioblastoma multiforme; report of a prospective study evaluating prognostic factors and analysing long term survival advantage. Int. J. Oncol. Biol. Phys., 30, 541 549.
27. MINETA T, RABKIN SD AND MARTUZA RL. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54, 3963 3966.
28. MINETA T, RABKIN SD, YAZAKI T, HUNTER WD AND MARTUZA RL. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med., 1, 938 943.
29. NOBLE M AND MURRAY K. (1984). Purified astrocytes promote the division of a hipotential glial progenitor cell. EMBO J., 3, 2243 2247.
30. OLDFIELD EH, RAM Z, CULVER K, BLAESE RM, DE VROOM HL AND ANDKRSON WF. (1993). Gene therapy for treatment of brain tumors using intra-tumoral transduction with thymidine kinase gene and intravenous ganciclovir. Human Gene Therapy, 4, 39 69.
31. 2 distribution and bioreductive enzymes in human malignant brain tumours. Int. J. Radiat. Oncol. Biol. Phys., 29, 427-431.
32. RANDAZZO RBP, KESARI S, GESSER RM, ALSOP D, FORD JC, BROWN SM, MACLEAN AR AND FRASER NW. (1995). Treatment of experimental intracranial murine melanoma with neuroattenuated herpes simplex virus type I mutant. Virology, 211, 94 101.
33. + gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen Virol, 75, 2059-2063.